Today: 19 July 2026
Browse Category

NYSE:NVS 11 August 2025 - 9 July 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for 2026. Reuters+3Reuters+3Reuters+3
20 December 2025
········
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago to the high-$40s this month ts2.tech. In the past three months alone, RNA jumped ~40%, fueled by upbeat clinical updates and M&A speculation ts2.tech. The stock hit a 52-week peak of $56 in early October ts2.tech after its lead DMD therapy showed strong results and secured FDA Breakthrough designation. Shares pulled back slightly to around $49 by late October, but remained up 100%+ year-over-year ts2.tech.
27 October 2025
·····
Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the massive value of RNA therapeutics for rare diseases – and signals that big pharma’s biotech spending spree isn’t slowing down. While Avidity’s chapter as an independent company is closing, its novel treatments may reach patients faster under Novartis’s umbrella. Investors now await the finalization of the deal, as Wall Street cheers another biotech success story in the making. 🏥💥
26 October 2025
····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction Washingtonpost. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil Washingtonpost Washingtonpost.
16 September 2025
·······
Undersea Cable Chaos, iPhone 17 “Air” Reveal & $500B Cloud Bombshell – The Biggest Tech News (Sept 9–10, 2025)

Undersea Cable Chaos, iPhone 17 “Air” Reveal & $500B Cloud Bombshell – The Biggest Tech News (Sept 9–10, 2025)

Apple’s latest devices on display at the September 9 launch event in Cupertino. Apple introduced its 2025 lineup of devices at a splashy Cupertino event. Leading the announcements was the iPhone 17 Air, Apple’s thinnest phone ever at just 5.6 mm reuters.com. This new “Air” model slots between the base iPhone 17 and the Pro flagships as a premium mid-tier option reuters.com. Despite its slim build, it packs the same high-end A19 Pro processor as the Pro, and Apple execs touted it as offering “MacBook Pro levels of compute in an iPhone” reuters.com. The standard iPhone 17 got a 6.3-inch high-refresh display and an upgraded 48 MP camera, while the iPhone 17 Pro introduced a new aluminum unibody design, a vapor-chamber cooling system for sustained performance, and up to 2 TB of storage – a first for iPhone reuters.com reuters.com.
10 September 2025
·······
Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

This 48-hour period brought a flurry of major developments in biotechnology, pharmaceuticals, medicine and public health worldwide – from game-changing clinical trial victories and regulatory decisions to urgent health policy actions and scientific breakthroughs. Below is a comprehensive roundup of the top news from August 10–11, 2025.
11 August 2025
····
Go toTop